Ovarian cancer often goes undetected until it spreads to other areas. In its late stages, it's harder to treat. Now there's an unconventional treatment being used to get rid of it. When her stomach ...

Amber and her family in the Volkswagen convertible she bought after learning she was cancer-free Amber used to live her life with anxiety and fear—always trying to stay within her comfort zone. She ...

A retrospective study compared progression-free and overall survival of hyperthermic intraperitoneal chemotherapy with conventional intraperitoneal chemotherapy in patients with ovarian cancer.

SCS combined with HIPEC may improve overall survival in PSROC patients compared to SCS alone, with a statistically significant benefit observed. The risk of severe complications, including anemia and ...

Median progression-free survival (PFS) improved from 23 months with surgery alone to 25 months with the addition of hyperthermic intraperitoneal chemotherapy (HIPEC), a nonsignificant difference. Post ...

Patients with stage IV colorectal cancer (CRC) had lower overall and disease-free survival if they had a pelvic exenteration (PE) or cytoreductive surgery and hyperthermic intraperitoneal chemotherapy ...

Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial This was a multicenter randomized phase ...

A new guideline from ASCO updates evidence-based recommendations on the use of neoadjuvant chemotherapy and interval cytoreduction versus primary cytoreductive surgery (PCS) and chemotherapy in ...